Review of economic evaluations of radiofrequency catheter ablation for cardiac arrhythmias

Canadian Journal of Cardiology

Volumn 19, Issue 11, 2003, Pages 1285-1304

  Marshall, Deborah A ^a   O'Brien, Bernie J O ^a   Nichol, Graham ^b  

^a CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Antiarrhythmia agents; Arrhythmia; Atrial fibrillation; Catheter ablation; Health economics; Health policy

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT;

BIOMEDICAL TECHNOLOGY ASSESSMENT; CATHETER ABLATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE CLASSIFICATION; ECONOMIC EVALUATION; HEALTH CARE COST; HEART ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MODEL; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; QUALITY ADJUSTED LIFE YEAR; RESOURCE MANAGEMENT; REVIEW; SENSITIVITY ANALYSIS; WOLFF PARKINSON WHITE SYNDROME;

ADULT; ARRHYTHMIA; CATHETER ABLATION; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; ONTARIO; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX;

EID: 0344980080     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Ostrander L, Brandt RL, Kjelsberg MD, Epstein FH. Electrocardiographic findings among the adult population of a total natural community. Circulation 1965;31:888-98.
2. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: The Framingham study. N Engl J Med 1982;306:1018-22.
3. Noorani HZ, Yee R, Marshall D, Connolly S, Nichol G, O'Brien B. Radiofrequency Catheter Ablation for Cardiac Arrhythmias: A Clinical and Economic Review. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2002.
4. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programs, 2nd edn. Toronto: Oxford University Press, 1997.
5. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. Oxford: Oxford University Press, 1996.
6. Zarnke KB, Levine MA, O'Brien BJ. Cost-benefit analyses in the health-care literature: Don't judge a study by its label. J Clin Epidemiol 1997;50:813-22.
7. Spilker B. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn. Philadelphia: Lippincott-Raven, 1996.
8. Kaplan RM, Anderson JP. A general health policy model: Update and applications. Health Serv Res 1988;23:203-35.
9. Torrance GW, Furlong W, Feeny D, Boyle KF. Multi-attribute preference functions: Health Utilities Index. Pharmacoeconomics 1995;7:503-20.
10. Kind P. The EuroQOL Instrument: An Index of Health-Related Quality of Life. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven, 1996:191-201.
11. Parkes J, Bryant J, Milne R. Implantable cardioverter defibrillators: Arrhythmias. A rapid and systematic review. Health Technol Assess 2000;4:1-69.
12. Griffith MJ, Bexton RS, McComb JM. Financial audit of antitachycardia pacing for the control of recurrent supraventricular tachycardia. Br Heart J 1993;69:272-5.
13. May CD, Davis MJ. The safety and economic advantages of day case electrophysiologic studies. Aust NZ J Med 1992;22:240-2.
14. Simpson CS, Yee R, Lee JK, et al. Safety and feasibility of a novel rate-smoothed ventricular pacing algorithm for atrial fibrillation. Am Heart J 2001;142:294-300.
15. Cheng CHF, Sanders GD, Heidenreich PA, et al. Cost effectiveness of radiofrequency ablation for treatment of paroxysmal supraventricular tachycardias. Med Decis Making 1998;18:458.
16. Hogenhuis W, Stevens SK, Wang P, et al. Cost-effectiveness of radiofrequency ablation in WPW syndrome. Circulation 1992;86(Suppl 4):I1-101.
17. Pitschner HF, Pluegge T, Neuzner J, Bahavar H, Schlepper M. Cost-benefit relation referring to radiofrequency catheter ablation in supraventricular tachycardias. A multicentre experience. Eur Heart J 1997;18(Suppl):427. (Abstr)
18. Navarro X, Brugada J, Matas M, Navarro-Lopez F. Cost-benefit analysis of radiofrequency ablation in paroxysmal supraventricular tachycardias in a university hospital in Spain. Eur Heart J 1995;16(Suppl):102. (Abstr)
19. Seidl K, Hauer B, Schilling I, Senges J. Radiofrequency catheter ablation versus antiarrhythmic drug therapy in patients with supraventricular tachycardia: Cost-effectiveness analysis. Eur Heart J 1994;15(Suppl):287. (Abstr)
20. Barker J, Griffith M, McComb J. Cost benefit analysis of radiofrequency ablation of accessory pathways. Eur Heart J 1994;15:270.
21. De Buitleir M, Sousa J, Calkins H, et al. Dramatic reduction in medical care costs associated with radiofrequency catheter ablation of accessory pathways. J Am Coll Cardiol 1991;17(Suppl A):109A.
22. Salerno-Uriarte J, Klersy C. Ablazione transcatetere della tachicardia ventricolare: Analisi costo-efficacia. Ital Heart J 2000;1(Suppl 5):715-6.
23. Pappone C, Santinelli V. Rassegna bibliografica ragionata: Costo-efficacia dell'ablazione mediante radiofrequenza della tachicardia sopraventricolare. Ital Heart J Suppl 2001;2:421-2.
24. Brignole M. A novel use of cardiac pacing to improve cardiac function in patients with heart failure and permanent atrial fibrillation. Europace 2001;3:150-2.
25. Brignole M, Gammage M. An assessment of the optimal ventricular pacing site in patients undergoing 'ablate and pace' therapy for permanent atrial fibrillation. Europace 2001;3:153-6.
26. Garson A Jr, Kanter RJ. Management of the child with Wolff-Parkinson-White syndrome and supraventricular tachycardia: Model for cost effectiveness. J Cardiovasc Electrophysiol 1997;8:1320-6.
27. Case CL, Gillette PC, Crawford FA, Knick BJ. Comparison of medical care costs between successful radiofrequency catheter ablation and surgical ablation of accessory pathways in the pediatric age group. Am J Cardiol 1994;73:600-1.
28. Wellens HJJ. Pulmonary vein ablation in atrial fibrillation hype or hope? Circulation 2000;102:2562-4.
29. Schilling RJ, Peters NS. An introduction to catheter ablation of arrhythmias. Br J Cardiol 2000;7:594,596-600.
30. Peters NS. Demystifying curative arrhythmia management. Br J Cardiol 2000;7:575.
31. Fitzpatrick AP. Impact on quality of life of HIS-bundle catheter ablation and permanent pacing: Measuring outcomes. Heart Fail 1997;13:43-46,52.
32. Wren C. Treatment of tachycardia in infants and children. Indian Pediatr 1999;36:1091-6.
33. Sopher SM, Camm AJ. New trials in atrial fibrillation. J Cardiovasc Electrophysiol 1998;9(Suppl 8):S211-5.
34. Basta M, Klein GJ, Yee R, Krahn A, Lee J. Current role of pharmacologic therapy for patients with paroxysmal supraventricular tachycardia. Cardiol Clin 1997;15:587-97.
35. Epstein AE, Miles WM, Benditt DG, et al. Personal and public safety issues related to arrhythmias that may affect consciousness: Implications for regulation and physician recommendations. A medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology. Circulation 1996;94:1147-66.
36. Radiofrequency catheter ablation for treatment of cardiac arrhythmias. Med Lett Drugs Ther 1996;38:40-2.
37. Hauer RNW, Wever EFD. Implantable cardioverter-defibrillator: Cost/benefit ratio. New Trends Arrhythmias 1991;7:837-42.
38. Hauer RN, Wever EF, Crijns HJ. Automatic implantable cardioverter defibrillator: Cost effectiveness. Pacing Clin Electrophysiol 1993;16:559-63.
39. Scheinman MM, North American Society of Pacing and Electrophysiology Ad Hoc Committee on Catheter Ablation. Catheter ablation for cardiac arrhythmias, personnel, and facilities. Pacing Clin Electrophysiol 1992;15:715-21.
40. Vora AM, Green MS, Tang ASL. Safety and feasibility of same day discharge in patients undergoing radiofrequency catheter ablation. Am J Cardiol 1998;81:233-5.
41. Joseph ME. ICD implantation: Cost conscious or patient conscious. J Cardiovasc Electrophysiol 1996;7:203-10.
42. DiMarco JP. Cardiac electrophysiology: A cost-effective approach. Clin Cardiol 1996;19:575-8.
43. Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Gardiner J. Cost-effectiveness analysis in heart disease, Part III: Ischemia, congestive heart failure, and arrhythmias. Prog Cardiovasc Dis 1995;37:307-46.
44. Jan S, Shiell A. Resource implications of medical interventions. Aust NZ J Med 1994;24:318.
45. American College of Cardiology Cardiovascular Technology Assessment Committee. Catheter ablation for cardiac arrhythmias: Clinical applications, personnel and facilities. J Am Coll Cardiol 1994;24:828.
46. Schilling RJ, Lamb DW, Peters NS. Selection and follow-up of patients undergoing electrophysiological study and radiofrequency catheter ablation. Br J Cardiol 2001;8:828-33.
47. Lupi G, Brignole M. Atrioventricular junction ablation and pacemaker in patients with heart failure and permanent atrial fibrillation. Ital Heart J 2001;2:573-6.
48. Lewalter T, Lüderitz B. Quality of life in atrial fibrillation: Relevance of the autonomic nervous system. Eur Heart J 2001;22: 196-7.
49. Calkins H. Radiofrequency catheter ablation of supraventricular arrhythmias. Heart 2001;85:594-600.
50. Asirvatham SJ, Friedman PA. Ablation for atrial fibrillation: Is the cure at hand? J Cardiovasc Electrophysiol 2001;12:909-11.
51. Cheng CHF, Sanders GD, Hlatky MA, et al. Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia. Ann Intern Med 2000;133;864-76.
52. Hogenhuis W, Stevens SK, Wang P, et al. Cost-effectiveness of radiofrequency ablation compared with other strategies in Wolff-Parkinson-White syndrome. Circulation 1993;88:437-46.
53. Calkins H, Bigger Jr JT, Ackerman SJ, et al. Cost-effectiveness of catheter ablation in patients with ventricular tachycardia. Circulation 2000;101:280-8.
54. Knight BT, Weiss R, Bahu M, et al. Cost comparison of radiofrequency modification and ablation of the atrioventricular junction in patients with chronic atrial fibrillation. Circulation 1997;96:1532-6.
55. Weerasooriya HR, Harris AH, Davis MJ. Cost effectiveness of day stay versus inpatient radiofrequency (RF) ablation for the treatment of supraventricular tachyarrhythmias. Aust NZ J Med 1996;26:206-9.
56. Kertes PJ, Kalman JM, Tonkin AM. Cost effectiveness of radiofrequency catheter ablation in the treatment of symptomatic supraventricular tachyarrhythmias. Aust NZ J Med 1993;23:433-6.
57. Kalbfleisch SJ, Calkins H, Langberg JJ, et al. Comparison of the cost of radiofrequency catheter modification of the atrioventricular node and medical therapy for drug-refractory atrioventricular node reentrant tachycardia. J Am Coll Cardiol 1992;19:1583-7.
58. De Buitleir M, Sousa J, Bolling SF, et al. Reduction in medical care cost associated with radiofrequency catheter ablation of accessory pathways. Am J Cardiol 1991;68:1656-61.
59. De Buitleir M, Bove EL, Schmaltz S, Kadish AH, Morady F. Cost of catheter versus surgical ablation in the Wolff-Parkinson-White syndrome. Am J Cardiol 1990;66:189-92.
60. Ikeda T, Sugi K, Enjoji Y, Kasao M, Abe R, Ninomiya K. Cost effectiveness of radiofrequency catheter ablation versus medical treatment for paroxysmal supraventricular tachycardia in Japan. J Cardiol 1994;24:461-8.
61. Weerasooriya HR, Murodock CJ, Harris AH, Davis MJ. The cost-effectiveness of treatment of supraventricular arrhythmias related to an accessory atrioventricular pathway: Comparison of catheter ablation, surgical division and medical treatment. Aust NZ J Med 1994;24:161-7.
62. Kalbfleisch SJ, El Atassi R, Calkins H, Langberg JJ, Morady F. Safety, feasibility and cost of outpatient radiofrequency catheter ablation of accessory atrioventricular connections. J Am Coll Cardiol 1993;21:567-70.
63. Man KC, Kalbfleisch SJ, Hummel JD, et al. Safety and cost of outpatient radiofrequency ablation of the slow pathway in patients with atrioventricular nodal reentrant tachycardia. Am J Cardiol 1993;72:1323-4.
64. Mitchell ARJ, Patel NR, Kamalvand K, Topham A, Paul VE, Sulke AN. Safety, effectiveness and cost efficacy of diagnostic electrophysiology and radiofrequency ablation in a district general hospital. Int J Clin Pract 2001;55:305-308.
65. Fragakis N, Kotsakis A, Patel N, et al. Atrial flutter ablation: Efficacy and cost-effectiveness of a single decapolar electrode to demonstrate bidirectional isthmus block. Europace 2001;3:304-10.
66. Larson MS, McDonald K, Young C, Sung R, Hlatky MA. Quality of life before and after radiofrequency catheter ablation in patients with drug refractory atrioventricular nodal reentrant tachycardia. Am J Cardiol 1999;84:471-3.
67. Bathina MN, Mickelsen S, Brooks C, Jaramillo J, Hepton T, Kusumoto FM. Radiofrequency catheter ablation versus medical therapy for initial treatment of supraventricular tachycardia and its impact on quality of life and healthcare costs. Am J Cardiol 1998;82:589-93.
68. Fitzpatrick AP, Kourouyan HD, Siu A, et al. Quality of life and outcomes after radiofrequency HIS-bundle catheter ablation and permanent pacemaker implantation: Impact of treatment in paroxysmal and established atrial fibrillation. Am Heart J 1996;131:499-507.
69. Sareewiwatthana P, Unhasuta K, Raungratanaampon Q. Quality of life of cardiac arrhythmia patients after radiofrequency catheter ablation. J Med Assoc Thai 1999;82:1041-7.
70. Levy T, Walker S, Mason M, et al. Importance of rate control or rate regulation for improving exercise capacity and quality of life in patients with permanent atrial fibrillation and normal left ventricular function: A randomised controlled study. Heart 2001;85:171-8.
71. Gerstenfeld EP, Guerra P, Sparks PB, Hattori K, Lesh MD. Clinical outcome after radiofrequency catheter ablation of focal atrial fibrillation triggers. J Cardiovasc Electrophysiol 2001;12:900-8.
72. Drummond M, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83.
73. Canadian Coordinating Office for Health Technology Assessment. Guidelines for Economic Evaluation of Pharmaceuticals: Canada. Ottawa: CCOHTA, 1994.
74. Ontario Guidelines for Economic Analysis of Pharmaceutical Products. Toronto: Ontario Ministry of Health and Long-Term Care, 1994
75. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8.
76. US Preventive Services Task Force. Guide to Clinical Preventive Services. Baltimore: Williams and Wilkins, 1989.
77. Canadian Task Force on Preventive Health Care. Colorectal cancer screening. Can Med Assoc J 2001;165:206-8.
78. Shmueli A. The SF-36 profile and health-related quality of life: An interpretative analysis. Qual Life Res 1998;7:187-95.
79. Finkler SA. The distinction between costs and charges. Ann Intern Med 1982;96:102-9.
80. Gravelle H, Smith D. Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Econ 2001;10:587-99.
81. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;196:716-21.
82. Black WC. A graphic representation of cost-effectiveness. Med Decis Making 1990;10:212-4.
83. Laupacis A, Feeny D, Detsky AS, Tugwell P. How attractive does a new technology have to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-81.
84. Johannesson M, Weinstein MC. On the decision rules of cost-effectiveness analysis. J Health Econ 1993;12:459-67.
85. Birch S, Gafni A. Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems. J Health Econ 1993;12:469-76.
86. Drummond MF, Torrance GW, Mason J. Cost-effectiveness league tables: More harm than good? Soc Sci Med 1993;37:33-40.
87. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985;5:157-77.
88. Briggs AH, Mooney CZ, Wonderling DE. Constructing confidence intervals around cost-effectiveness ratios: An evaluation of parametric and non-parametric methods using Monte Carlo simulation. Stat Med 1999;18:3245-62.